CA2701534C - Intermediates and methods for the synthesis of halichondrin b analogs - Google Patents

Intermediates and methods for the synthesis of halichondrin b analogs Download PDF

Info

Publication number
CA2701534C
CA2701534C CA2701534A CA2701534A CA2701534C CA 2701534 C CA2701534 C CA 2701534C CA 2701534 A CA2701534 A CA 2701534A CA 2701534 A CA2701534 A CA 2701534A CA 2701534 C CA2701534 C CA 2701534C
Authority
CA
Canada
Prior art keywords
compound
alkyl
formula
protecting group
cyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2701534A
Other languages
English (en)
French (fr)
Other versions
CA2701534A1 (en
Inventor
Charles Chase
Atsushi Endo
Francis G. Fang
Jing Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2701534(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CA2701534A1 publication Critical patent/CA2701534A1/en
Application granted granted Critical
Publication of CA2701534C publication Critical patent/CA2701534C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/28Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
CA2701534A 2007-10-03 2008-10-03 Intermediates and methods for the synthesis of halichondrin b analogs Active CA2701534C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99762507P 2007-10-03 2007-10-03
US60/997,625 2007-10-03
PCT/US2008/078762 WO2009046308A1 (en) 2007-10-03 2008-10-03 Intermediates and methods for the synthesis of halichondrin b analogs

Publications (2)

Publication Number Publication Date
CA2701534A1 CA2701534A1 (en) 2009-04-09
CA2701534C true CA2701534C (en) 2017-02-21

Family

ID=40019255

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2701534A Active CA2701534C (en) 2007-10-03 2008-10-03 Intermediates and methods for the synthesis of halichondrin b analogs

Country Status (11)

Country Link
US (6) US8093410B2 (OSRAM)
EP (2) EP2200992B1 (OSRAM)
JP (1) JP5735277B2 (OSRAM)
CN (3) CN101883763B (OSRAM)
BR (1) BRPI0817909B1 (OSRAM)
CA (1) CA2701534C (OSRAM)
IL (1) IL204791A (OSRAM)
MX (1) MX2010003599A (OSRAM)
RU (1) RU2489437C2 (OSRAM)
SG (1) SG10201811715YA (OSRAM)
WO (1) WO2009046308A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2682878B2 (ja) 1989-11-27 1997-11-26 上村工業株式会社 シールド付き電気めっき装置
AU762998B2 (en) 1998-06-17 2003-07-10 Eisai R&D Management Co., Ltd. Macrocyclic analogs and methods of their use and preparation
JP5226304B2 (ja) 2004-06-03 2013-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類似体の調製用中間体
SG10201811715YA (en) 2007-10-03 2019-02-27 Eisai R&D Man Co Ltd Intermediates and methods for the synthesis of halichondrin b analogs
EP2274309B1 (en) 2008-04-04 2015-07-29 Eisai R&D Management Co., Ltd. Halichondrin b analogs
DE102009012660A1 (de) * 2009-03-13 2010-09-16 H.C. Starck Clevios Gmbh Polymerbeschichtungen mit verbesserter Temperaturstabilität
PT2415470T (pt) 2009-03-30 2016-08-31 Eisai R&D Man Co Ltd Composição de lipossomas
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
CN102225921B (zh) * 2011-04-26 2013-04-24 中国人民解放军第二军医大学 一种环戊烷聚酮类化合物simplextone A及其用途
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
KR20150090921A (ko) 2012-12-04 2015-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료에서 에리불린의 용도
WO2014208774A1 (en) 2013-06-26 2014-12-31 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
EP3689881B1 (en) 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
CN105916861B (zh) 2013-12-06 2018-12-14 卫材R&D管理有限公司 可用于合成软海绵素b类似物的方法
AU2015267099B2 (en) 2014-05-28 2020-08-27 Eisai R&D Management Co., Ltd Use of eribulin in the treatment of cancer
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
EP3191479B1 (en) 2014-09-09 2020-04-08 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
BR112017018872A2 (pt) 2015-03-04 2018-05-29 Eisai R&D Man Co Ltd combinação de um antagonista pd-1 e eribulina para tratamento de câncer
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
EP3292130B1 (en) 2015-05-07 2020-09-30 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
CN108601760A (zh) 2016-02-12 2018-09-28 卫材R&D管理有限公司 艾日布林的合成中的中间体及相关的合成方法
JOP20170053B1 (ar) 2016-03-02 2021-08-17 Eisai Randd Man Co Ltd مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
CN109641917B (zh) * 2016-06-30 2022-06-14 卫材R&D管理有限公司 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体
US20190263927A1 (en) 2016-10-14 2019-08-29 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
ES2931533T3 (es) 2017-04-05 2022-12-30 Harvard College Compuesto macrocíclico y usos del mismo
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
EP3710454B1 (en) 2017-11-15 2024-01-03 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2019136145A1 (en) 2018-01-03 2019-07-11 Eisai R&D Management Co., Ltd. Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
JP7574232B2 (ja) 2019-06-21 2024-10-28 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ ホモプロパルギルアルコールを調製するための化学酵素的プロセス
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2027890C3 (de) * 1970-06-06 1979-02-01 Kali Chemie Ag 8-AIkoxy oder -Benzyloxy-3-methyl-lO- methylen-2,9-dioxatricyclo-(43,l,03,7 )-decan-4-one und 8-AIkoxy oder 8-Benzyloxy-3,10-dimethyl-2,9dioxatricyclo- (43,1,O" )-decan-4-one
SU652180A1 (ru) 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US4086245A (en) * 1976-12-09 1978-04-25 The Upjohn Company Antibiotics 7-O-alkylnogarols
SU722912A1 (ru) * 1978-03-06 1980-03-25 Уфимский Нефтяной Институт Способ получени 5-метил/-4оксо3,6,8-триоксабицикло/ (3,2,1)-октана
US5436238A (en) * 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (OSRAM) 1992-09-09 1995-09-01 Hoechst Ag
JP2001500498A (ja) 1996-09-06 2001-01-16 イーライ・リリー・アンド・カンパニー 触媒選択的スルホニル化法
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
AU762998B2 (en) * 1998-06-17 2003-07-10 Eisai R&D Management Co., Ltd. Macrocyclic analogs and methods of their use and preparation
DE10106647A1 (de) 2001-02-12 2002-08-22 Univ Hannover Ratjadon-Derivate zum Hemmen des Zellwachstums
CN108997267A (zh) * 2004-06-03 2018-12-14 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
JP5226304B2 (ja) 2004-06-03 2013-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類似体の調製用中間体
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
JP2009510005A (ja) 2005-09-26 2009-03-12 シムライズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツト・ゲゼルシヤフト 分子内プリンス反応および該反応に適する触媒
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
JPWO2009014105A1 (ja) 2007-07-20 2010-10-07 株式会社山田養蜂場本社 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
SG10201811715YA (en) * 2007-10-03 2019-02-27 Eisai R&D Man Co Ltd Intermediates and methods for the synthesis of halichondrin b analogs
US20090203771A1 (en) * 2007-11-16 2009-08-13 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
EP2274309B1 (en) 2008-04-04 2015-07-29 Eisai R&D Management Co., Ltd. Halichondrin b analogs
JP5371091B2 (ja) 2009-01-23 2013-12-18 三菱レイヨン株式会社 モノスルホン酸エステルの製造方法
BR112012018232B8 (pt) * 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
AU2012344697A1 (en) 2011-11-30 2014-07-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
EP2831082B1 (en) 2012-03-30 2019-02-20 Sandoz AG Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
JP6511613B2 (ja) 2013-07-03 2019-05-15 サンド・アクチエンゲゼルシヤフト ハリコンドリンBの大環状C1−ケト類似体の製造のための合成方法及び該方法に有用な中間体、例えば−SO2−(p−トリル)基を含有する中間体
EP3689881B1 (en) 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
CN105916861B (zh) 2013-12-06 2018-12-14 卫材R&D管理有限公司 可用于合成软海绵素b类似物的方法
EP3191479B1 (en) 2014-09-09 2020-04-08 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
EP3292130B1 (en) 2015-05-07 2020-09-30 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
CN108601760A (zh) 2016-02-12 2018-09-28 卫材R&D管理有限公司 艾日布林的合成中的中间体及相关的合成方法
CN109641917B (zh) 2016-06-30 2022-06-14 卫材R&D管理有限公司 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体
WO2018217894A1 (en) 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
WO2019136145A1 (en) 2018-01-03 2019-07-11 Eisai R&D Management Co., Ltd. Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof

Also Published As

Publication number Publication date
EP2578576A1 (en) 2013-04-10
CN104311571A (zh) 2015-01-28
US10214539B2 (en) 2019-02-26
CN101883763A (zh) 2010-11-10
US20190263826A1 (en) 2019-08-29
CN108948039B (zh) 2021-12-31
IL204791A (en) 2017-06-29
US9802953B2 (en) 2017-10-31
US9604993B2 (en) 2017-03-28
MX2010003599A (es) 2010-09-10
EP2578576B9 (en) 2016-09-14
RU2489437C2 (ru) 2013-08-10
CA2701534A1 (en) 2009-04-09
WO2009046308A1 (en) 2009-04-09
BRPI0817909B1 (pt) 2022-06-21
US20160214992A1 (en) 2016-07-28
EP2200992B1 (en) 2014-02-26
US20150225415A1 (en) 2015-08-13
US8093410B2 (en) 2012-01-10
RU2010117520A (ru) 2011-11-10
JP5735277B2 (ja) 2015-06-17
EP2578576B1 (en) 2016-03-23
US8987479B2 (en) 2015-03-24
US20120095242A1 (en) 2012-04-19
US20090198074A1 (en) 2009-08-06
EP2200992A1 (en) 2010-06-30
CN104311571B (zh) 2019-07-02
JP2010540658A (ja) 2010-12-24
US20180037588A1 (en) 2018-02-08
US10717743B2 (en) 2020-07-21
IL204791A0 (en) 2010-11-30
CN101883763B (zh) 2016-04-20
CN108948039A (zh) 2018-12-07
SG10201811715YA (en) 2019-02-27
BRPI0817909A2 (pt) 2015-04-07

Similar Documents

Publication Publication Date Title
CA2701534C (en) Intermediates and methods for the synthesis of halichondrin b analogs
CA2219675C (en) Pentacyclic compound
JP2018522944A (ja) カンナビジオール及びδ−9−テトラヒドロカンナビノールの生成のためのプロセス
HUP0402140A2 (hu) Eljárás hexahidrofuro [2,3-b]furán-3-ol előállítására
CN1938316A (zh) 制备(3R,3aS,6aR)六氢-呋喃并[2,3-b]呋喃-3-醇的方法
JP7442663B2 (ja) Sglt阻害剤の合成に有用な中間体およびこれを用いたsglt阻害剤の製造方法
WO2020155613A1 (zh) 一种海鞘素化合物及其中间体的制备方法
CA2902009A1 (en) Isohexide monotriflates and process for synthesis thereof
AU2011271489A1 (en) Preparation of tesetaxel and related compounds and corresponding synthesis intermediate
Fernández et al. Stereocontrolled transformation of nitrohexofuranoses into cyclopentylamines via 2-oxabicyclo [2.2. 1] heptanes. IV: Synthesis of enantiopure methyl (1S, 2R, 3R, 4R, 5S)-5-benzyloxycarbonylamino-2, 3-isopropylidenedioxy-4-methoxycyclopentanecarboxylate
Pimpalpalle et al. Lewis acid-catalyzed stereoselective lactonization and subsequent glycosidation of 2-C-malonyl carbohydrates
TANAKA et al. Synthetic Studies on a Picrotoxane Sesquiterpene, Coriamyrtin. I. The Grignard Reaction of 5-(2-Methyl-1, 3-dioxo-2-cyclopentyl) methyl-2, 5H-furanone with Isopropenylmagnesium Bromide and Stereochemistries of the Products
JP2000229961A (ja) ヒドロナフト[2,3−c]フラン誘導体およびその製造方法
WO2001047906A1 (en) Process for the production of 5-oxy-7-oxabicyclo-[4.1.0]hept-3-e ne-3-carboxylic acid esters
Horneman et al. Highly Functionalised Cyclopentanes by Radical Cyclisation of Unsaturated Bromolactones III. Preparation of Carbaaldohexofuranoses. Determination of the Relative Configuration at C-4/C-5 of 2, 3-Unsaturated Heptono-1, 4-lactones by Means of 1H NMR Spectroscopy
WO2023276983A1 (ja) ベラプロストまたは光学活性体の合成中間体およびその製造方法
田中圭 et al. Synthetic studies on a picrotoxane sesquiterpene, coriamyrtin. I. The Grignard reaction of 5-(2-methyl-1, 3-dioxo-2-cyclopentyl) methyl-2, 5H-furanone with isopropenylmagnesium bromide and stereochemistries of the products.
JPS60197662A (ja) カ−バメ−ト及びその製法
WO2012075122A2 (en) Processes and intermediates for preparing substituted hexahydrofuro [2,3-b] furans
JPWO1996033998A1 (ja) 五環性化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130927